Will mTOR inhibitors make it as cancer drugs?

被引：165

作者：

Sawyers, CL ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA

来源：

CANCER CELL | 2003年 / 4卷 / 05期

关键词：

D O I：

10.1016/S1535-6108(03)00275-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

收藏

页码：343 / 348

页数：6

相关论文

共 55 条

[1] Identification of TOR signaling complexes: more TORC for the cell growth engine
Abraham, RT
[J]. CELL, 2002, 111 (01) : 9 - 12
[2] Allander SV, 2001, CANCER RES, V61, P8624
[3] A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt
Aoki, M
Blazek, E
Vogt, PK
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) : 136 - 141
[4] ATKINS MB, 2002, P ASCO, V21, pA36
[5] Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
Bianco, R
Shin, I
Ritter, CA
Yakes, FM
Basso, A
Rosen, N
Tsurutani, J
Dennis, PA
Mills, GB
Arteaga, CL
[J]. ONCOGENE, 2003, 22 (18) : 2812 - 2822
[6] Choe G, 2003, CANCER RES, V63, P2742
[7] Clark GJ, 1997, J BIOL CHEM, V272, P10608
[8] Targeting epidermal growth factor receptor - are we missing the mark?
Dancey, JE
Freidlin, B
[J]. LANCET, 2003, 362 (9377) : 62 - 64
[9] Clinical development of mammalian target of rapamycin inhibitors
Dancey, JE
[J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2002, 16 (05) : 1101 - +
[10] NEW ANTI-TUMOR SUBSTANCES OF NATURAL ORIGIN
DOUROS, J
SUFFNESS, M
[J]. CANCER TREATMENT REVIEWS, 1981, 8 (01) : 63 - 87

← 1 2 3 4 5 6 →